Results 41 to 50 of about 15,900 (130)

Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study

open access: yesJournal of Hematology & Oncology, 2021
Ibrutinib plus venetoclax, given with an ibrutinib lead-in, has shown encouraging clinical activity in early phase studies in mantle cell lymphoma (MCL).
Michael Wang   +14 more
doaj   +1 more source

Ibrutinib versus rituximab in relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma: a randomized, open‐label phase 3 study

open access: yesCancer Medicine, 2018
In the Asia‐Pacific region, treatment options are limited for patients with relapsed/refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
Xiaojun Huang   +22 more
doaj   +1 more source

GPR83 protects cochlear hair cells against ibrutinib-induced hearing loss through AKT signaling pathways

open access: yesFrontiers in Medicine
IntroductionIbrutinib, widely used in leukemia treatment, has been implicated in sensorineural hearing loss; however, its underlying mechanisms remain unclear.MethodsThis study investigated the impact of ibrutinib on hearing using HEI-OC1 cells, cochlear
Yuhua Zhang   +9 more
doaj   +1 more source

Ibrutinib inhibits antibody dependent cellular cytotoxicity induced by rituximab or obinutuzumab in MCL cell lines, not overcome by addition of lenalidomide

open access: yesExperimental Hematology & Oncology, 2019
Background The Bruton’s Tyrosine Kinase (BTK)-inhibitor ibrutinib is highly active in mantle cell lymphoma (MCL) but may inhibit response to anti-CD20 antibody as previously shown in CLL models.
Alexandra Albertsson-Lindblad   +3 more
doaj   +1 more source

Btk inhibitor ibrutinib reduces inflammatory myeloid cell responses in the lung during murine pneumococcal pneumonia

open access: yesMolecular Medicine, 2019
Background Streptococcus pneumoniae is a major causative agent in community-acquired pneumonia and sepsis. Overwhelming lung inflammation during pneumococcal pneumonia may hamper lung function.
Alexander P. de Porto   +7 more
doaj   +1 more source

Mitigating Ibrutinib‐Induced Ventricular Arrhythmia and Cardiac Dysfunction With Metformin

open access: yesCancer Innovation
Background Ibrutinib is a first‐line drug that targets Bruton's tyrosine kinase for the treatment of B cell cancer. However, cardiotoxicity induced by ibrutinib is a major side effect that limits its clinical use.
Pengsha Li   +13 more
doaj   +1 more source

Hypertension in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma in ALPINE: a secondary analysis

open access: yesBlood Neoplasia
: Hypertension is a common side effect of Bruton tyrosine kinase inhibitors (BTKis). The second-generation BTKi zanubrutinib has high BTK selectivity, which may minimize off-target effects.
June-Wha Rhee   +6 more
doaj   +1 more source

Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis

open access: yesHaematologica, 2018
Clinical trials that led to ibrutinib’s approval for the treatment of chronic lymphocytic leukemia showed that its side effects differ from those of traditional chemotherapy.
Anthony R. Mato   +25 more
doaj   +1 more source

Portuguese real-world experience with ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma

open access: yesFrontiers in Hematology
BackgroundMantle cell lymphoma is usually characterized by an aggressive and recurrent course. Clinical trials and real-world series have demonstrated clinical benefits with the use of ibrutinib as a second-line treatment, compared to later relapses ...
Catarina Fernandes   +22 more
doaj   +1 more source

Home - About - Disclaimer - Privacy